ABVC BioPharma Inc (NASDAQ:ABVC) shares, rose in value on Thursday, July 10, with the stock price down by -28.42% to the previous day’s close as strong demand from buyers drove the stock to $3.35.
Actively observing the price movement in the last trading, the stock closed the session at $4.68, falling within a range of $3.28 and $4.95. The value of beta (5-year monthly) was 0.186. Referring to stock’s 52-week performance, its high was $5.48, and the low was $0.40. On the whole, ABVC has fluctuated by 106.79% over the past month.
With the market capitalization of ABVC BioPharma Inc currently standing at about $56.89 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2023-May-15.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ABVC’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of ABVC currently trading nearly 29.96% and 82.27% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 59.48, while the 7-day volatility ratio is showing 28.97% which for the 30-day chart, stands at 15.90%. Furthermore, ABVC BioPharma Inc (ABVC)’s beta value is 0.24.
A comparison of ABVC BioPharma Inc (ABVC) with its peers suggests the former has fared considerably weaker in the market. ABVC showed an intraday change of -28.42% in last session, and over the past year, it grew by 467.80%%.
Data on historical trading for ABVC BioPharma Inc (NASDAQ:ABVC) indicates that the trading volumes over the past 10 days have averaged 1.0 and over the past 3 months, they’ve averaged 390.70K. According to company’s latest data on outstanding shares, there are 15.38 million shares outstanding.
Nearly 14.33% of ABVC BioPharma Inc’s shares belong to company insiders and institutional investors own 1.69% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.51 million shares as on 2025-06-13, resulting in a short ratio of 1.48. According to the data, the short interest in ABVC BioPharma Inc (ABVC) stood at 357.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 0.44 million. The stock has risen by 346.37% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABVC stock heading into the next quarter.
